Sagimet Biosciences Inc.(SGMT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SGMT Sagimet Biosciences Inc.

Closed 10-22 16:00:00 EDT

9.95

-0.04

-0.40%

盘后10.00

+0.05+0.50%

19:52 EDT

High10.15	Low9.63	Vol1.01M
Open10.00	D1 Closing9.99	Amplitude5.23%
Mkt Cap705.54M	Tradable Cap672.81M	Total Shares70.91M
T/O9.94M	T/O Rate1.49%	Tradable Shares67.62M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"SGMT","market":"US","secType":"STK","nameCN":"Sagimet Biosciences Inc.","latestPrice":9.95,"timestamp":1792699200000,"preClose":9.99,"halted":0,"volume":1006778,"hourTrading":{"tag":"盘后","latestPrice":10,"preClose":9.95,"latestTime":"19:52 EDT","volume":11578,"amount":115208.544,"timestamp":1792713166471,"change":0.05,"changeRate":0.005025,"amplitude":0.005025},"delay":0,"changeRate":-0.004004004004004097,"floatShares":67619256,"shares":70908700,"eps":-1.248952,"marketStatus":"Closed","change":-0.04,"latestTime":"10-22 16:00:00 EDT","open":10,"high":10.15,"low":9.628,"amount":9935570.919818,"amplitude":0.052252,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.248952,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1792742400000},"marketStatusCode":5,"adr":0,"listingDate":1689307200000,"exchange":"NASDAQ","adjPreClose":9.99,"preHourTrading":{"tag":"盘前","latestPrice":10.01,"preClose":9.99,"latestTime":"09:29 EDT","volume":1554,"amount":15255.297876,"timestamp":1792675799999,"change":0.02,"changeRate":0.002002,"amplitude":0.109109},"postHourTrading":{"tag":"盘后","latestPrice":10,"preClose":9.95,"latestTime":"19:52 EDT","volume":11578,"amount":115208.544,"timestamp":1792713166471,"change":0.05,"changeRate":0.005025,"amplitude":0.005025},"volumeRatio":0.637621,"impliedVol":0.954,"impliedVolPercentile":0.243},"requestUrl":"/m/hq/s/SGMT/wiki","defaultTab":"wiki","newsList":[{"id":"2677181918","title":"Ascletis Partner Sagimet Starts Pivotal U.S. Phase III Trial of Acne Drug Denifanstat","url":"https://stock-news.laohu8.com/highlight/detail?id=2677181918","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677181918?lang=en_us&edition=fundamental","pubTime":"2026-10-23 08:08","pubTimestamp":1792714136,"startTime":"0","endTime":"0","summary":"Ascletis Pharma, Inc. ( ($HK:1672) ) has provided an announcement. Ascletis’ strategic partner Sagimet Biosciences has dosed the first patient in A...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ascletis-partner-sagimet-starts-pivotal-u-s-phase-iii-trial-of-acne-drug-denifanstat?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ascletis-partner-sagimet-starts-pivotal-u-s-phase-iii-trial-of-acne-drug-denifanstat?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SGMT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677952100","title":"Sagimet Doses First Patient in U.S. Phase 3 Trial of Denifanstat for Acne","url":"https://stock-news.laohu8.com/highlight/detail?id=2677952100","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677952100?lang=en_us&edition=fundamental","pubTime":"2026-10-22 19:08","pubTimestamp":1792667299,"startTime":"0","endTime":"0","summary":"Sagimet Doses First Patient in U.S. Phase 3 Trial of Denifanstat for AcneSagimet Biosciences dosed the first patient in its pivotal U.S. AURORA Phase 3 trial of oral denifanstat for moderate to severe","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261022:nNDL7S3hYG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2W23.USD","IE00BQXX3D17.EUR","IE00BKPKM429.USD","BK4588","IE00BQXX3C00.GBP","SGMT","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD","BK4112","SG9999014021.USD","SG9999014039.USD","BK4585","IE00BQXX3F31.USD","IE00B64PRP62.GBP","LU2210149790.SGD","IE00BGHQF748.EUR","NDAQ","LU0314104364.USD","BCDF","SG9999014013.SGD","BK4139","LU2095319765.USD","IE00BN0W2V16.EUR","SG9999014005.SGD","LU2210150020.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674396856","title":"Sagimet Says Partner Trial Shows Denifanstat Sustains Acne Efficacy Through 52 Weeks","url":"https://stock-news.laohu8.com/highlight/detail?id=2674396856","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674396856?lang=en_us&edition=fundamental","pubTime":"2026-10-09 19:01","pubTimestamp":1791543662,"startTime":"0","endTime":"0","summary":"Sagimet says partner trial shows denifanstat sustains acne efficacy through 52 weeksSagimet flagged positive 52-week acne data for oral denifanstat from Ascletis’ Phase 3 open-label extension in China","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261009:nNDL2rRvcQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","LU2210149790.SGD","SG9999014005.SGD","BK4139","IE00BKPKM429.USD","IE00BN0W2W23.USD","BCDF","BK4585","LU2095319765.USD","BK4112","NDAQ","LU0314104364.USD","IE00BQXX3F31.USD","SG9999014013.SGD","BK4588","SG9999014039.USD","IE00BGHQF748.EUR","IE00B64PRP62.GBP","LU2210150020.SGD","IE00BQXX3C00.GBP","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD","IE00BN0W2V16.EUR","SGMT","IE00BQXX3D17.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673018387","title":"Sagimet Biosciences Price Target Maintained with a $29.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2673018387","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673018387?lang=en_us&edition=fundamental","pubTime":"2026-10-05 18:25","pubTimestamp":1791195900,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SGMT/analyst-ratings","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672193937","title":"Sagimet Biosciences price target raised to $26 from $25 at Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2672193937","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672193937?lang=en_us&edition=fundamental","pubTime":"2026-10-02 18:50","pubTimestamp":1790938239,"startTime":"0","endTime":"0","summary":"Guggenheim raised the firm’s price target on Sagimet Biosciences (SGMT) to $26 from $25 and keeps a Buy rating on the shares. With the denifanstat ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/sagimet-biosciences-price-target-raised-to-26-from-25-at-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/sagimet-biosciences-price-target-raised-to-26-from-25-at-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SGMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672767136","title":"Sagimet Biosciences Closes Offering of Shares, Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2672767136","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672767136?lang=en_us&edition=fundamental","pubTime":"2026-10-02 05:30","pubTimestamp":1790890214,"startTime":"0","endTime":"0","summary":"Sagimet Biosciences  closed an offering of nearly 8.8 million series A common shares at $10 apiece and pre-funded warrants to buy 2.8 million common shares at $9.99 per warrant for gross proceeds of $115 million, it said late Thursday.The pre-funded warrants are exercisable immediately, according to a statement.Net proceeds will be used to fund a phase 3 clinical trial for denifanstat in acne, TVB-3567 through phase 2 topline results, advance a topical formulation FASN inhibitor program to investigational new drug application submission, and for general corporate purposes, the company said.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","SGMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672762347","title":"Sagimet Biosciences Announces Closing of Underwritten Offering of Series a Common Stock and Pre-Funded Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2672762347","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672762347?lang=en_us&edition=fundamental","pubTime":"2026-10-02 04:31","pubTimestamp":1790886671,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nTUA3BDGFG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SGMT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672762524","title":"Sagimet Biosciences Announces Closing of Underwritten Offering of Series A Common Stock and Pre-Funded Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2672762524","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672762524?lang=en_us&edition=fundamental","pubTime":"2026-10-02 04:31","pubTimestamp":1790886660,"startTime":"0","endTime":"0","summary":"FOSTER CITY, Calif., Oct.  01, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabo","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/01/3373424/0/en/sagimet-biosciences-announces-closing-of-underwritten-offering-of-series-a-common-stock-and-pre-funded-warrants.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SGMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672376584","title":"Sagimet Biosciences Phase 3 Trial of Denifanstat as Acne Treatment Has High Success Probability, Wedbush Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2672376584","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672376584?lang=en_us&edition=fundamental","pubTime":"2026-10-01 23:32","pubTimestamp":1790868741,"startTime":"0","endTime":"0","summary":"Sagimet Biosciences' (SGMT) planned phase 3 study of denifanstat as acne treatment should have a high probability of success based on previous clinical data and expert opinion, Wedbush Securities said","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","SGMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672768856","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Sanofi (OtherSNYNF), Sagimet Biosciences, Inc. Class A (SGMT) and Eli Lilly & Co (LLY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2672768856","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672768856?lang=en_us&edition=fundamental","pubTime":"2026-10-01 21:50","pubTimestamp":1790862609,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Sanofi (SNYNF), Sagimet Biosciences, Inc. Class A ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-sanofi-othersnynf-sagimet-biosciences-inc-class-a-sgmt-and-eli-lilly-co-lly-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-sanofi-othersnynf-sagimet-biosciences-inc-class-a-sgmt-and-eli-lilly-co-lly-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2168564495.EUR","LU2456880835.USD","AGNG","LU2552382058.USD","GB00BDT5M118.USD","IE0001KFT4U8.USD","LU2264538146.SGD","LU1868837136.USD","SGXZ99366536.SGD","LU0122379950.USD","LU2361045086.USD","LU2028103732.USD","SG9999001176.USD","LU1868836757.USD","LU0354030511.USD","LU0096364046.USD","LU1145028129.USD","LU2237443895.HKD","MEDX","LU2756315318.SGD","CURE","LU1623119135.USD","OZEM","LU0820561909.HKD","LU1551013425.SGD","LU0820561818.USD","LU2237443382.USD","MHIP","LU2089283258.USD","CANC","IE00BFSS7M15.SGD","LU1291159041.SGD","LU0345770993.USD","LU2462591350.SGD","LU1989771016.USD","LU2746668461.USD","ELIL","LU2063271972.USD","IE00BJJMRZ35.SGD","LU2357305700.SGD","LU2756315664.SGD","LU2750360997.AUD","FHLC","LU1061106388.HKD","LU0006306889.USD","LU1691799644.USD","LU0320765992.SGD","IE0005OL40V9.USD","LU0174119429.USD","SGXZ31699556.SGD","THNR","LU0385154629.USD","SG9999018857.SGD","LU2237438978.USD","PPH","IE00B4R5TH58.HKD","SG9999001176.SGD","SNYNF","LU0708995401.HKD","LU0198837287.USD","IE00BK4W5M84.HKD","LU2750360641.GBP","LU0234572021.USD","LU2087625088.SGD","LU0079474960.USD","LU1988902786.USD","LU0353189763.USD","IE00BK4W5L77.USD","LU2471134523.USD","WDNA","LU0158827948.USD","IE00BWXC8680.SGD","LU1093756325.SGD","LLY","LU0683600562.USD","LU0417517546.SGD","LU0210536198.USD","LU2168564065.EUR","IE0004445239.USD","VHT","IE00BFSS8Q28.SGD","SGXZ51526630.SGD","ILDR","LU2112291526.USD","LU2211815571.USD","LU0061475181.USD","BK4533","LU2089284900.SGD","LU0203202063.USD","BK4588","LU1720051017.SGD","FTXH","IE00B1BXHZ80.USD","LU0354030438.USD","LU0097036916.USD","LU1057294990.SGD","LLYZ","LU0203201768.USD","LU0225283273.USD","LU0823416689.USD","LU0823434583.USD","LU0823434740.USD","LU0058720904.USD","LU2111349929.HKD","LU2236285917.USD","LU2552382132.HKD","SG9999015952.SGD","LU2237443465.HKD","LU0158827781.USD","SG9999015978.USD","LU0882574139.USD","IE00B4JS1V06.HKD","LU1064131342.USD","HRTS","IE0009355771.USD","TRUH","BK4139","IE00B1XK9C88.USD","LU2471134952.CNY","IE00BJJMRY28.SGD","IE00BFTCPJ56.SGD","LU2023250504.SGD","LU1280957306.USD","LU0289739699.SGD","LU2461242641.AUD","LU0323591593.USD","BK4516","LU2108987350.USD","BK4581","SGXZ81514606.USD","LU2896262040.SGD","LU0640476718.USD","LU1974910355.USD","LLII","LU2023250330.USD","LU1979441026.SGD","LU1093756168.USD","LU0133085943.USD","LU0471298694.HKD","LU0471298777.SGD","LU1868837300.USD","LU0114720955.EUR","LU1917777945.USD","LU2213496289.HKD","LU0689472784.USD","LU1023059063.AUD","LU2237443549.SGD","LU2491050154.USD","LU0256863811.USD","LU2265009873.SGD","LU2106854487.HKD","MEDI","SG9999014906.USD","BK4007","LU0882574055.USD","LU0432979614.USD","LU0889565916.HKD","IE00BJT1NW94.SGD","LU0266013472.USD","TMED","LU2089984988.USD","LU0256863902.USD","LU1548497426.USD","LU1551013342.USD","SG9999013999.USD","LU2237443622.USD","IE00BKDWB100.SGD","IE00BJLML261.HKD","LU2168563687.JPY","SG9999018865.SGD","LU2271345857.HKD","LU2491049909.HKD","IE00BJJMRX11.SGD","IE0002141913.USD","LU1720051108.HKD","LU1868836591.USD","BK4599","LU1323610961.USD","LU1804176565.USD","LU0964807845.USD","LU0094547139.USD","LU1814569148.SGD","LU1868836914.USD","LU2324357040.USD","LU2491050071.SGD","SG9999017495.SGD","LU0787776722.HKD","LU2360106947.USD","LU0109394709.USD","LU0466842654.USD","SG9999014898.SGD","JDOC","LU0320765059.SGD","LU0345770308.USD","LU0316494557.USD","LU2237443978.SGD","LU2468319806.SGD","LU0238689110.USD","LU2602419157.SGD","LU0353189680.USD","LU1267930730.SGD","LU2361044949.HKD","LU2168564149.EUR","IE0004445015.USD","LLYX","IE00BKPKM429.USD","GDOC","IHE","LU0820562030.AUD","LU1232071149.USD","LU2471134879.HKD","LU0786609619.USD","IE00BN29S564.USD","SGMT","SGXZ57979304.SGD","LU1127390331.HKD","LU2168564222.USD","LU2471134796.USD","LU2361044865.SGD","LU1366192091.USD","ELIS","IE00B7KXQ091.USD","IXJ","LU1629891620.HKD","LU1035775433.USD","IE00B775H168.HKD","IYH","LU0109391861.USD","LU2417539215.USD","LU2552382215.SGD","LU1069344957.HKD","LU0943347566.SGD","PJP","LU1983299246.USD","LU2462157665.USD","LU2746668974.SGD","SG9999015945.SGD","SG9999014880.SGD","LU2023251221.USD","BK4534","LU0672654240.SGD","IE00B2B36J28.USD","RXL","SG9999015986.USD","SG9999014914.USD","LU0456855351.SGD","LU1712237335.SGD","BK4585","LU0106261372.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672757806","title":"Oppenheimer Adjusts Price Target on Sagimet Biosciences to $38 From $33, Maintains Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2672757806","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672757806?lang=en_us&edition=fundamental","pubTime":"2026-10-01 20:46","pubTimestamp":1790858791,"startTime":"0","endTime":"0","summary":"Sagimet Biosciences (SGMT) has an average rating of buy and mean price target of $27.85, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SGMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672752921","title":"Sagimet Biosciences Inc. : Oppenheimer Raises Target Price to $38 from $33","url":"https://stock-news.laohu8.com/highlight/detail?id=2672752921","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672752921?lang=en_us&edition=fundamental","pubTime":"2026-10-01 20:25","pubTimestamp":1790857555,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nAZN4TN37K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SGMT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672759581","title":"Sagimet Biosciences Announces Major Equity Financing Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2672759581","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672759581?lang=en_us&edition=fundamental","pubTime":"2026-10-01 18:36","pubTimestamp":1790850985,"startTime":"0","endTime":"0","summary":"Sagimet Biosciences, Inc. Class A ( ($SGMT) ) has issued an update. On September 30, 2026, Sagimet Biosciences Inc. entered into an underwriting ag...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/sagimet-biosciences-announces-major-equity-financing-agreement?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/sagimet-biosciences-announces-major-equity-financing-agreement?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4215","BK4585","BK4139","REZ","SGMT","EQR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672780990","title":"Sagimet Biosciences’ China data strengthens denifanstat case, says Clear Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2672780990","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672780990?lang=en_us&edition=fundamental","pubTime":"2026-10-01 05:50","pubTimestamp":1790805012,"startTime":"0","endTime":"0","summary":"Clear Street keeps a buy rating and $28 price target on Sagimet Biosciences (SGMT) after the company presented its Phase 3 ASC40-304 OLE clinical t...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/sagimet-biosciences-china-data-strengthens-denifanstat-case-says-clear-street-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/sagimet-biosciences-china-data-strengthens-denifanstat-case-says-clear-street-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SGMT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671205720","title":"Sagimet Prices $115 Million Offering of Series A Shares, Warrants; Shares Rise Pre-Bell","url":"https://stock-news.laohu8.com/highlight/detail?id=2671205720","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671205720?lang=en_us&edition=fundamental","pubTime":"2026-09-30 18:59","pubTimestamp":1790765987,"startTime":"0","endTime":"0","summary":"Sagimet Biosciences  priced an offering of about 8.8 million shares of series A common stock at $10 per share for gross proceeds of approximately $115 million, the company said Wednesday.The company also priced pre-funded warrants to purchase approximately 2.8 million shares at $9.9999 per warrant.Sagimet expects the offering to generate about $115 million in fross proceeds.Commodore Capital leads the offering, with participation from RA Capital Management, Spruce Street Capital, BVF Partners, Aberdeen Investments, Columbia Threadneedle Investments, Affinity Asset Advisors and Woodline Partners.Net proceeds from the offering, together with existing cash and cash equivalents, will be used to fund a phase 3 trial of denifanstat in acne and pre-launch activities, to advance TVB-3567 through phase 2 topline results, and to advance its topical FASN inhibitor program toward an investigational new drug submission.Sagimet plans to use some of the proceeds for general corporate purposes, includ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","SGMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671055402","title":"Sagimet Biosciences prices 8.75M shares at $10.00 in underwritten offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2671055402","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671055402?lang=en_us&edition=fundamental","pubTime":"2026-09-30 18:25","pubTimestamp":1790763916,"startTime":"0","endTime":"0","summary":"Sagimet Biosciences (SGMT) announced the pricing of an underwritten offering of 8,750,010 shares of its Series A common stock at a price of $10.00 ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/sagimet-biosciences-prices-8-75m-shares-at-10-00-in-underwritten-offering-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/sagimet-biosciences-prices-8-75m-shares-at-10-00-in-underwritten-offering-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","SGMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671203533","title":"Sagimet Biosciences - Prices 8.8 Mln Series a Common Shares at $10 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2671203533","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671203533?lang=en_us&edition=fundamental","pubTime":"2026-09-30 18:19","pubTimestamp":1790763559,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260930:nTUA43LB6T:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SGMT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671035362","title":"Sagimet Biosciences Announces Pricing of $115.0 Million Underwritten Offering of Series a Common Stock and Pre-Funded Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2671035362","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671035362?lang=en_us&edition=fundamental","pubTime":"2026-09-30 18:19","pubTimestamp":1790763559,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260930:nTUA43LB6T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SGMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671039012","title":"Sagimet Biosciences Announces Pricing of $115.0 Million Underwritten Offering of Series A Common Stock and Pre-Funded Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2671039012","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671039012?lang=en_us&edition=fundamental","pubTime":"2026-09-30 18:19","pubTimestamp":1790763540,"startTime":"0","endTime":"0","summary":"FOSTER CITY, Calif., Sept.  30, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metab","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/30/3371706/0/en/sagimet-biosciences-announces-pricing-of-115-0-million-underwritten-offering-of-series-a-common-stock-and-pre-funded-warrants.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SGMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671203363","title":"Sagimet Biosciences - Suspends and Terminates ATM Prospectus Supplement for Series a Common Stock Effective Sept 30","url":"https://stock-news.laohu8.com/highlight/detail?id=2671203363","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671203363?lang=en_us&edition=fundamental","pubTime":"2026-09-30 18:15","pubTimestamp":1790763320,"startTime":"0","endTime":"0","summary":"BRIEF-Sagimet Biosciences - Suspends And Terminates ATM Prospectus Supplement For Series A Common Stock Effective Sept 30Sept 30 -Sagimet Biosciences Inc.SGMT.O:SAGIMET BIOSCIENCES - SUSPENDS AND TERMINATES ATM PROSPECTUS SUPPLEMENT FOR SERIES A COMMON STOCK EFFECTIVE SEPT 30 - SEC FILINGFurther company coverage:SGMT.O","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260930:nFWN45M0HV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGMT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sagimet.com","stockEarnings":[{"period":"1week","weight":0.3241},{"period":"1month","weight":-0.075},{"period":"3month","weight":0.4251},{"period":"6month","weight":0.7048},{"period":"1year","weight":0.2841},{"period":"ytd","weight":0.6875}],"compareEarnings":[{"period":"1week","weight":0.0045},{"period":"1month","weight":-0.0005},{"period":"3month","weight":0.0473},{"period":"6month","weight":0.0829},{"period":"1year","weight":0.1516},{"period":"ytd","weight":0.1337}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":0.228208},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.167334},{"month":3,"riseRate":0,"avgChangeRate":-0.107746},{"month":4,"riseRate":0.666667,"avgChangeRate":0.104894},{"month":5,"riseRate":0.666667,"avgChangeRate":0.101166},{"month":6,"riseRate":0.666667,"avgChangeRate":0.282829},{"month":7,"riseRate":0.333333,"avgChangeRate":0.014223},{"month":8,"riseRate":0.25,"avgChangeRate":-0.004679},{"month":9,"riseRate":0,"avgChangeRate":-0.12394},{"month":10,"riseRate":0.75,"avgChangeRate":0.132058},{"month":11,"riseRate":0.666667,"avgChangeRate":-0.001337},{"month":12,"riseRate":0.333333,"avgChangeRate":0.009885}],"exchange":"NASDAQ","name":"Sagimet Biosciences Inc.","nameEN":"Sagimet Biosciences Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Sagimet Biosciences Inc.(SGMT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Sagimet Biosciences Inc.(SGMT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Sagimet Biosciences Inc.,SGMT,Sagimet Biosciences Inc.股票,Sagimet Biosciences Inc.股票老虎,Sagimet Biosciences Inc.股票老虎国际,Sagimet Biosciences Inc.行情,Sagimet Biosciences Inc.股票行情,Sagimet Biosciences Inc.股价,Sagimet Biosciences Inc.股市,Sagimet Biosciences Inc.股票价格,Sagimet Biosciences Inc.股票交易,Sagimet Biosciences Inc.股票购买,Sagimet Biosciences Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Sagimet Biosciences Inc.(SGMT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Sagimet Biosciences Inc.(SGMT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction